alias:: Neonatal hyperbilirubinemia
ICD-11_Code:: JC20.0
tags:: disease, paediatrics, neonatology

- ## Etiology
  background-color:: blue
	- ### Causative Agents
		- Unconjugated hyperbilirubinemia (most common)
		- Conjugated hyperbilirubinemia (pathologic)
	- ### Risk Factors
		- Prematurity
		- Breastfeeding (insufficient intake)
		- Blood group incompatibility (ABO, Rh)
		- Cephalohematoma
		- East Asian ethnicity
		- G6PD deficiency
		- Polycythemia
- ## Epidemiology
  background-color:: blue
	- ### Incidence
		- 60% of term neonates
		- 80% of preterm neonates
	- ### Prevalence
		- ### Demographics
			- More common in East Asian infants
			- Male predominance
	- ### Geographic Distribution
		- Worldwide distribution
- ## Pathophysiology
  background-color:: blue
	- ### Mechanism of Disease
		- Increased bilirubin production (hemolysis)
		- Decreased bilirubin conjugation (immature liver)
		- Impaired bilirubin excretion
		- Enterohepatic circulation
	- ### Affected Systems/Organs
		- Liver
		- Brain (kernicterus in severe cases)
		- Skin
- ## Clinical Features
  background-color:: blue
	- ### Clinical Presentation
		- #### Symptoms
			- Yellow skin discoloration
			- Poor feeding
			- Lethargy (in severe cases)
		- #### Signs
			- Yellow sclera
			- Cephalocaudal progression of jaundice
	- ### Stages or Classification
		- Physiologic jaundice
		- Pathologic jaundice
			- | Severity | Total Serum Bilirubin (TSB) | Clinical Significance |
			  | ---- | ---- | ---- |
			  | **Mild** | **<6 mg/dL (102 μmol/L)** | Usually physiological, but requires monitoring if rising rapidly. |
			  | **Moderate** | **6–8 mg/dL (102–136 μmol/L)** | Needs evaluation for possible pathological causes (e.g., hemolysis, infection). |
			  | **Severe** | **>8 mg/dL (136 μmol/L)** | **Pathologic jaundice**—requires urgent evaluation (e.g., hemolytic disease, sepsis). |
			- | **Category** | **Phototherapy Start (mg/dL)** | **Exchange Transfusion (mg/dL)** | **Incidence** | **Duration** | **Key Notes** |
			  | ---- | ---- | ---- |
			  | **Term Infant (≥38wks)** |  |  | **60-80%** | **5-7 days** | Physiological jaundice peaks at **3-5 days**. |
			  | **- ≤24h** | **≥8** (always pathologic) | **≥12-15** (if hemolysis) | **<1%** | Requires urgent workup | Check for **ABO/Rh, sepsis, G6PD**. |
			  | **- 24-48h** | **≥12** | **≥20** | **10-15%** | 1-2 weeks if hemolytic | Intensive PT if **≥15-18**. |
			  | **- 49-72h** | **≥15** | **≥22** | **20-30%** | Resolves by 1-2 weeks | Monitor for **breastmilk jaundice**. |
			  | **- >72h** | **≥17-18** | **≥25** | **5-10%** | May persist 3-12 weeks if breastfeeding-related | Rule out **hypothyroidism, biliary atresia**. |
			  | **Preterm Infant (35-37wks)** | **Lower (~10-12 at 24h)** | **≥15-20** | **80-90%** | **7-14 days** | Higher risk of **kernicterus at lower levels**. |
			  | **Preterm (<35wks)** | **≥5-8** | **≥12-15** | **>90%** | **2-4 weeks** | Aggressive PT; **albumin binding matters**. |
			  | **Hemolytic (e.g., ABO/Rh)** | **Start PT 2-3mg/dL lower** | **≥5mg/dL above PT threshold** | **5-10% of jaundiced newborns** | **1-3 weeks** | **Exchange if TSB rising >0.5mg/dL/hr**. |
			  | **Breastfeeding Jaundice** | **≥17-20** (if no other risks) | Rarely needed | **10-30% of BF infants** | **3-12 weeks** | Due to **low intake/dehydration**; resolves with feeding support. |
			  | **Breastmilk Jaundice** | **≥15-18** (if persistent) | Almost never | **2-4%** | **3-12 weeks** | Caused by **pregnanediol in milk**; benign if no other issues. |
			  | **G6PD Deficiency** | **Start PT earlier (≥10 at 24h)** | **≥18-20** (high neurotoxicity risk) | **Varies by ethnicity (5-30% in high-prevalence groups)** | **1-3 weeks** | **Avoid oxidative stressors** (e.g., sulfa drugs, fava beans). |
		- Breast milk jaundice
		- Breastfeeding jaundice
- ## Diagnosis
  background-color:: blue
	- ### Diagnostic Criteria
		- Visual assessment
		- Transcutaneous bilirubinometry
		- Serum bilirubin levels
	- ### Investigation
		- ### Establishing Diagnosis
			- Bilirubin levels (total and direct)
			- Blood type and Coombs test
			- Complete blood count
			- Reticulocyte count
		- ### Ruling Out Differential Diagnosis
			- | **Differential Diagnosis** | **Shared Features** | **Clinical Exclusion** | **Baseline Workup** (Perform even if no suspicion) | **Direct Testing** (Perform if suspicion) |
			  |---|---|---|---|---|
			  | Biliary atresia | Jaundice | Pale stools, dark urine | Liver function tests | HIDA scan, liver biopsy |
			  | Sepsis | Lethargy, poor feeding | Fever, hypotension | CBC, CRP | Blood culture |
			  | Hemolytic disease | Jaundice, anemia | Positive Coombs test | Blood type, Coombs test | G6PD assay |
		- ### General Assessment
			- Kramer's rule for clinical estimation
			- Hour-specific bilirubin nomogram
- ## Management and Treatment
  background-color:: blue
	- ### Medical Treatment
		- Phototherapy
			- Term: ≥15 mg/dL (first 48 hrs), ≥18 mg/dL (>72 hrs).
			- Preterm: Lower thresholds (e.g., ≥10–14 mg/dL).
		- Intravenous immunoglobulin (for isoimmune hemolysis)
		  *If hemolytic disease*
		- Exchange transfusion (severe cases)
			- **If**: ≥20–25 mg/dL (risk of **kernicterus**).
	- ### Surgical Options
		- None typically
	- ### Lifestyle and Dietary Recommendations
		- Frequent breastfeeding
		- Supplementation if inadequate intake
	- ### Follow-up
		- Early follow-up after discharge
		- Repeat bilirubin checks as needed
- ## Prognosis
  background-color:: blue
	- ### Expected Course
		- #### With Treatment
			- Excellent prognosis
			- Resolution within 1-2 weeks
		- #### Without Treatment
			- ##### Possible Complications
				- Acute bilirubin encephalopathy
				- Kernicterus
			- ##### Long-Term Effects
				- Cerebral palsy
				- Hearing loss
				- Intellectual disability
	- ### Survival Rates
		- #### With Treatment
			- Nearly 100%
		- #### Without Treatment
			- High mortality in kernicterus cases
	- ### Quality of Life Considerations
		- Excellent with proper management
- ## Prevention
  background-color:: blue
	- ### Health Education
		- Parental education about jaundice recognition
	- ### Community Approach
		- Universal screening programs
	- ### Screening Programs
		- Predischarge bilirubin screening
		- Risk factor assessment
	- ### Lifestyle Modifications
		- Ensure adequate feeding
- ## Patient Education and Support
  background-color:: blue
	- ### Educational Resources
		- AAP guidelines for parents
	- ### Support Groups
		- Kernicterus prevention networks
	- ### Counseling Options
		- For families affected by kernicterus
- ## Recent Research and Developments
  background-color:: blue
	- ### Ongoing Clinical Trials
		- Novel phototherapy techniques
		- Pharmacologic treatments
	- ### Recent Advances
		- Improved hour-specific nomograms
		- Better kernicterus prediction models
- ## Key Literature
  background-color:: blue
	- American Academy of Pediatrics guidelines
	- Bhutani nomogram studies
- ## Guidelines and Protocols
  background-color:: blue
	- AAP Clinical Practice Guideline
	- NICE guidelines (UK)